Extended-duration Betrixaban Versus Shorter-duration Enoxaparin for Venous Thromboembolism Prophylaxis in Critically Ill Medical Patients: an APEX Trial Substudy

Overview

Journal Intensive Care Med

Specialty Critical Care

Date 2019 Feb 20

PMID 30778649

Citations 8

Authors

Gerald Chi

C Michael Gibson

Arzu Kalayci

Alexander T Cohen

Adrian F Hernandez

Russell D Hull

Farima Kahe

Mehrian Jafarizade

Sadaf Sharfaei

Yuyin Liu

Robert A Harrington

Samuel Z Goldhaber

Affiliations

Soon will be listed here.

Abstract

Purpose: To assess the efficacy and safety of betrixaban for venous thromboembolism (VTE) prophylaxis among critically ill patients.

Methods: The APEX trial randomized 7513 acutely ill hospitalized patients to betrixaban for 35-42 days or enoxaparin for 10 ± 4 days. Among those, 703 critically ill patients admitted to the intensive care unit were included in the analysis, and 547 patients who had no severe renal insufficiency or P-glycoprotein inhibitor use were included in the full-dose stratum. The risk of VTE, bleeding, net clinical benefit (composite of VTE and major bleeding), and mortality was compared at 35-42 days and at 77 days.

Results: At 35-42 days, extended betrixaban reduced the risk of VTE (4.27% vs 7.95%, P = 0.042) without causing excess major bleeding (1.14% vs 3.13%, P = 0.07). Both VTE (3.32% vs 8.33%, P = 0.013) and major bleeding (0.00% vs 3.26%, P = 0.003) were decreased in the full-dose stratum. Patients who received betrixaban had more non-major bleeding than enoxaparin (overall population: 2.56% vs 0.28%, P = 0.011; full-dose stratum: 3.32% vs 0.36%, P = 0.010). Mortality was similar at the end of study (overall population: 13.39% vs 16.19%, P = 0.30; full-dose stratum: 13.65% vs 16.30%, P = 0.39).

Conclusions: Compared with shorter-duration enoxaparin, critically ill medical patients who received extended-duration betrixaban had fewer VTE without more major bleeding events. The benefit of betrixaban was driven by preventing asymptomatic thrombosis and offset by an elevated risk of non-major bleeding. The APEX trial did not stratify by intensive care unit admission and the present study included a highly selected population of critically ill patients. These hypothesis-generating findings need to be validated in future studies.

Clinical Trial Registration: http://www.clinicaltrials.gov . Unique identifier: NCT01583218.

Citing Articles

Standard- versus extended-duration anticoagulation for primary venous thromboembolism prophylaxis in acutely ill medical patients.

Kolkailah A, Abdelghaffar B, Elshafeey F, Magdy R, Kamel M, Abuelnaga Y Cochrane Database Syst Rev. 2024; 12:CD014541.

PMID: 39629741 PMC: 11616008. DOI: 10.1002/14651858.CD014541.pub2.

Pathophysiological dynamics in the contact, coagulation, and complement systems during sepsis: Potential targets for nafamostat mesilate.

He Q, Wei Y, Qian Y, Zhong M J Intensive Med. 2024; 4(4):453-467.

PMID: 39310056 PMC: 11411436. DOI: 10.1016/j.jointm.2024.02.003.

Neutrophil extracellular traps mediate deep vein thrombosis: from mechanism to therapy.

Yao M, Ma J, Wu D, Fang C, Wang Z, Guo T Front Immunol. 2023; 14:1198952.

PMID: 37680629 PMC: 10482110. DOI: 10.3389/fimmu.2023.1198952.

Current Opinion on the use of Direct Oral Anticoagulants for the Prophylaxis of Venous Thromboembolism among Medical Inpatients.

Lee J, Memar Montazerin S, Shojaei F, Chi G Ther Clin Risk Manag. 2021; 17:471-487.

PMID: 34079269 PMC: 8165214. DOI: 10.2147/TCRM.S271439.

Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study.

Longhitano Y, Racca F, Zanza C, Muncinelli M, Guagliano A, Peretti E Biology (Basel). 2020; 9(10).

PMID: 32987902 PMC: 7600769. DOI: 10.3390/biology9100310.

References

Kearon C . Natural history of venous thromboembolism. Circulation. 2003; 107(23 Suppl 1):I22-30. DOI: 10.1161/01.CIR.0000078464.82671.78. View

Chi G, Goldhaber S, Hull R, Hernandez A, Kerneis M, Al Khalfan F . Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. Thromb Haemost. 2017; 117(12):2389-2395. DOI: 10.1160/TH17-08-0538. View

Cade J . High risk of the critically ill for venous thromboembolism. Crit Care Med. 1982; 10(7):448-50. DOI: 10.1097/00003246-198207000-00006. View

Bergqvist D, Agnelli G, Cohen A, Eldor A, Nilsson P, Dietrich-Neto F . Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002; 346(13):975-80. DOI: 10.1056/NEJMoa012385. View

Geerts W, Cook D, Selby R, Etchells E . Venous thromboembolism and its prevention in critical care. J Crit Care. 2002; 17(2):95-104. DOI: 10.1053/jcrc.2002.33941. View

Chi G, Goldhaber S, Kittelson J, Turpie A, Hernandez A, Hull R . Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. J Thromb Haemost. 2017; 15(10):1913-1922. DOI: 10.1111/jth.13783. View

Rhodes A, Evans L, Alhazzani W, Levy M, Antonelli M, Ferrer R . Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017; 43(3):304-377. DOI: 10.1007/s00134-017-4683-6. View

Spyropoulos A, Anderson Jr F, FitzGerald G, Decousus H, Pini M, Chong B . Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011; 140(3):706-714. DOI: 10.1378/chest.10-1944. View

Amin A, Varker H, Princic N, Lin J, Thompson S, Johnston S . Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med. 2011; 7(3):231-8. DOI: 10.1002/jhm.1002. View

10.

Markel A . Origin and natural history of deep vein thrombosis of the legs. Semin Vasc Med. 2005; 5(1):65-74. DOI: 10.1055/s-2005-871743. View

11.

Lippi G, Tripodi A, Simundic A, Favaloro E . International survey on D-dimer test reporting: a call for standardization. Semin Thromb Hemost. 2015; 41(3):287-93. DOI: 10.1055/s-0035-1549092. View

12.

Levy J, Douketis J, Weitz J . Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol. 2018; 15(5):273-281. DOI: 10.1038/nrcardio.2017.223. View

13.

Cohen A, Harrington R, Goldhaber S, Hull R, Gibson C, Hernandez A . The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. Am Heart J. 2014; 167(3):335-41. DOI: 10.1016/j.ahj.2013.11.006. View

14.

Kahn S, Lim W, Dunn A, Cushman M, Dentali F, Akl E . Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e195S-e226S. PMC: 3278052. DOI: 10.1378/chest.11-2296. View

15.

Eikelboom J, Quinlan D, Douketis J . Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet. 2001; 358(9275):9-15. DOI: 10.1016/S0140-6736(00)05249-1. View

16.

Cook D, Griffith L, Walter S, Guyatt G, Meade M, Heyland D . The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care. 2001; 5(6):368-75. PMC: 83859. DOI: 10.1186/cc1071. View

17.

Hull R, Pineo G, Stein P, Mah A, MacIsaac S, Dahl O . Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001; 135(10):858-69. DOI: 10.7326/0003-4819-135-10-200111200-00006. View

18.

Eriksson B, Lassen M . Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2003; 163(11):1337-42. DOI: 10.1001/archinte.163.11.1337. View

19.

Bagshaw S, Stelfox H, Iwashyna T, Bellomo R, Zuege D, Wang X . Timing of onset of persistent critical illness: a multi-centre retrospective cohort study. Intensive Care Med. 2018; 44(12):2134-2144. DOI: 10.1007/s00134-018-5440-1. View

20.

Vaitkus P, Leizorovicz A, Cohen A, Turpie A, Olsson C, Goldhaber S . Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost. 2005; 93(1):76-9. DOI: 10.1160/TH04-05-0323. View